The US FDA's EMDAC Supports Provention Bio's Teplizumab in Delaying Diabetes
Shots:
- EMDAC has voted 10-7- confirming that the benefits of teplizumab outweigh the risks supporting the approval to delay T1D Mellitus
- The recommendation is based on a pivotal TN-10 study in which a single 14-day course of teplizumab delayed insulin-dependent- clinical-stage disease by a median of at least 2yrs. in pre symptomatic patients with stage 2 T1D compared to PBO
- The US FDA has granted BTD and PR to teplizumab’s BLA. The anticipated PDUFA date is July 2- 2021
Ref: PRNewswire | Image: PRNewswire
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com